JAVELIN Bladder 100 Trial: Strong Avelumab Maintenance Efficacy in High BMI Patients

Get the key insights in this MEDtalk from the JAVELIN Bladder 100 trial’s subgroup analysis presented at ASCO GU, focusing on patients with metastatic urothelial cancer and high BMI (≥30). Dr. Jeanny Aragon-Ching elaborates from data showing avelumab maintenance therapy’s significant impact on enhancing overall and progression-free survival rates for this patient group, overcoming the treatment complexities often encountered with high BMI cases.